OBJECTIVE

Although magnesium may favorably affect metabolic outcomes, few studies have investigated the role of magnesium intake in systemic inflammation and endothelial dysfunction in humans.

RESEARCH DESIGN AND METHODS

Among 3,713 postmenopausal women aged 50–79 years in the Women's Health Initiative Observational Study and free of cardiovascular disease, cancer, and diabetes at baseline, we measured plasma concentrations of high-sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6), turnor necrosis factor-α receptor 2 (TNF-α-R2), soluble intercellular adhesion molecule-1 (sICAM-1), soluble vascular cell adhesion molecule-1 (sVCAM-1), and E-selectin. Magnesium intake was assessed using a semiquantitative food frequency questionnaire.

RESULTS

After adjustment for age, ethnicity, clinical center, time of blood draw, smoking, alcohol, physical activity, energy intake, BMI, and diabetes status, magnesium intake was inversely associated with hs-CRP (P for linear trend = 0.003), IL-6 (P < 0.0001), TNF-α-R2 (P = 0.0006), and sVCAM-1 (P = 0.06). Similar findings remained after further adjustment for dietary fiber, fruit, vegetables, folate, and saturated and trans fat intake. Multivariable-adjusted geometric means across increasing quintiles of magnesium intake were 3.08, 2.63, 2.31, 2.53, and 2.16 mg/l for hs-CRP (P = 0.005); 2.91, 2.63, 2.45, 2.27, and 2.26 pg/ml for IL-6 (P = 0.0005); and 707, 681, 673, 671, and 656 ng/ml for sVCAM-1 (P = 0.04). An increase of 100 mg/day magnesium was inversely associated with hs-CRP (−0.23 mg/l ± 0.07; P = 0.002), IL-6 (−0.14 ± 0.05 pg/ml; P = 0.004), TNF-α-R2 (−0.04 ± 0.02 pg/ml; P = 0.06), and sVCAM-1 (−0.04 ± 0.02 ng/ml; P = 0.07). No significant ethnic differences were observed.

CONCLUSIONS

High magnesium intake is associated with lower concentrations of certain markers of systemic inflammation and endothelial dysfunction in postmenopausal women.

Magnesium is a biologically active mineral that acts as a cofactor in hundreds of enzymatic reactions in the human body. In observational studies, magnesium intake has been inversely associated with metabolic disease outcomes including hypertension (1), type 2 diabetes (2), cardiovascular disease (3), and colorectal cancer (4). The biological mechanism underlying these relations is not entirely clear, although experimental data in animals indicate that dietary magnesium deficiency may promote an inflammatory response (5), ultimately leading to endothelial dysfunction and metabolic disease. Available data in humans also suggest that low magnesium intake may be related to dyslipidemia (1) and insulin resistance (2). Although magnesium intake has been inversely associated with high-sensitivity C-reactive protein (hs-CRP) (1,6) in white women, its associations with interleukin-6 (IL-6) and tumor necrosis factor (TNF)-α (6,7) have been inconsistent. In addition, evidence regarding the relation of magnesium intake to endothelial dysfunction as measured by elevated concentrations of adhesion molecules is limited (6,8). Studies assessing dietary magnesium intake in relation to inflammation and endothelial markers in minority populations are lacking, and it is not known whether there are ethnic differences modifying this relation.

We therefore examined comprehensively the association between dietary magnesium intake and circulating concentrations of biomarkers of systemic inflammation (hs-CRP, IL-6, and TNF-α receptor 2 [TNF-α-R2]) and endothelial dysfunction (soluble intercellular adhesion molecule-1 [sICAM-1], soluble vascular cell adhesion molecule-1 [sVCAM-1], and E-selectin) in an ethnically diverse cohort of postmenopausal women aged 50–79 years enrolled in the Women's Health Initiative Observational Study (WHI-OS), including whites, African American, Hispanics, and Asians/Pacific Islanders.

The WHI-OS is an ongoing national health study designed to examine demographic, lifestyle, dietary, and biological factors on health outcomes among postmenopausal women. Details on design and recruitment have been published elsewhere (9,10). In brief, a total of 93,676 postmenopausal women aged 50–79 years were enrolled in the WHI-OS between September 1994 and December 1998 from 40 clinical centers nationwide. Eligible participants completed baseline demographic and dietary questionnaires, underwent physical examinations, and provided fasting blood samples. All WHI study procedures were approved by human subject review at each clinical center, and all women provided informed consent before participating.

For the current study, we included all participants from a case-control study of type 2 diabetes nested within the WHI-OS (n = 3,713), because all were free of cardiovascular disease, type 2 diabetes, and cancers at baseline. Details of this diabetes ancillary study have been published elsewhere (11,12).

Baseline measurements

Certified WHI trained staff measured height, weight, hip circumference, and blood pressure at the baseline visit. BMI (measured as weight in kilograms divided by the square of height in meters) was calculated. Standardized questionnaires including information on age, ethnicity, education, income, occupation, medical and family history, smoking status, alcohol use, recreational physical activity, and medication and supplement use were administered. A semiquantitative food frequency questionnaire (FFQ) used previously among similar populations (13,14) was used to assess food and nutrient intake in the last 3 months. The nutrient database for the WHI FFQ was derived from the University of Minnesota Nutrition Coding Center (Minneapolis, MN) nutrient database (15). All dietary nutrient variables were adjusted for total energy intake using the residual method (16). The energy-adjusted correlation coefficient for dietary magnesium intake comparing the FFQ with 8 days of dietary intake (four 24-h recalls and a 4-day food record) among the WHI postmenopausal female population was reported to be 0.7, indicating that the WHI FFQ reasonably captures short-term intake of dietary magnesium in this population (17).

Blood collection and assessment of biomarkers

Fasting blood specimens were collected from all participants at baseline according to a standardized protocol. Aliquots of serum, plasma, and buffy coat were frozen and shipped on dry ice to a central repository and stored at −70°C for future assays in outside laboratories. hs-CRP was measured on a chemistry analyzer (Hitachi 911; Roche Diagnostics, Indianapolis, IN) using an immunoturbidimetric assay with reagents and calibrators (Denka Seiken, Niigata, Japan). IL-6 was measured by an ultrasensitive enzyme-linked immunosorbent assay (R&D Systems, Minneapolis, MN). TNF-α-R2, sICAM-1, sVCAM-1, and E-selectin were measured by an enzyme-linked immunosorbent assay (R&D Systems). The coefficients of variation for each analyte were 1.61% for hs-CRP, 7.6% for IL-6, 3.5% for TNF-α-R2 (11), 6.7% for sICAM-1, 8.9% for sVCAM-1, and 6.5% for E-selectin (12).

Statistical analysis

The distributions of hs-CRP, IL-6, TNF-α-R2, sICAM-1, sVCAM-1, and E-selectin were highly skewed, and thus log transformations were performed to achieve normal distributions. Multiple linear regression models (using PROC GLM) were used to compute geometric means of inflammatory and endothelial biomarkers across quintiles of dietary magnesium after adjustment for potential confounding variables. Geometric means were calculated by regressing the natural logarithmic values of the plasma concentration of inflammatory and endothelial biomarkers on dietary magnesium intake and taking the antilog of the resulting mean logarithmic value. Tests of linear trend across increasing quintiles of dietary magnesium intake were conducted by using the median value of each quintile as a continuous variable in the model. Regression coefficients for the change in inflammatory and endothelial biomarkers for an increase of 100 mg/day dietary magnesium stratified by ethnicity were also calculated using linear regression models. All multivariable models were adjusted for matching factors (age, ethnicity [white, African American, Hispanic/Latino, and Asian/Pacific Islander], clinical center, and time of blood draw), smoking status (never, past, and current), alcohol (never, past, and current drinkers), physical activity measured by expenditure of energy from recreational activity (continuous), total energy intake (continuous), BMI (continuous), and type 2 diabetes case-control status (case and control subjects). To specifically address the independent association of magnesium intake, the final multivariate models were further adjusted for dietary fiber intake and other dietary factors such as fruit (continuous), vegetable (continuous), folate (continuous), trans fat (continuous), and saturated fat (continuous) intake. Variance inflation factors were examined for all models to check for multicollinearity issues. To further assess potential effect modification, subgroup analyses with prespecified factors including ethnicity (white, African American, Hispanic/Latino, and Asian/Pacific Islander), BMI (<25 and ≥25 kg/m2), smoking status (never smokers and ever smokers [current and past smokers]), alcohol intake (nondrinkers and current drinkers), and dietary fiber intake (low fiber intake [<21 g/day] and high fiber intake [≥21 g/day]) were conducted. The Wald test was used to assess the significance of multiplicative interaction terms. To account for measurement error, we further conducted a deattenuation analysis using a regression coefficient relating the dietary magnesium measurement from the baseline FFQ to 8 days of food records obtained from 113 women in the WHI (17,18).

All P values were two-tailed, and P < 0.05 was considered to indicate statistical significance unless otherwise specified. All statistical analyses were conducted using SAS software (version 9.1; SAS Institute, Cary, NC).

Characteristics of participants are summarized in Table 1. On average, African Americans had a higher BMI, higher smoking rate, higher dietary fat intake, and lower intake of dietary fiber and total magnesium than women in other ethnic groups. Asian/Pacific Islanders had lower concentrations of hs-CRP, IL-6, TNF-α-R2, sICAM-1, and E-selectin than did other ethnic groups, whereas African Americans had higher concentrations of hs-CRP and IL-6.

Table 1

Baseline characteristics according to ethnicity among postmenopausal women in the WHI-OS

Race/ethnicity
WhiteAfrican AmericanHispanic/LatinoAsian/Pacific Islander
n 1,922 1,123 423 245 
Mean age (years) 64 ± 6.9 61.0 ± 6.7 60 ± 6.8 64 ± 7.6 
Mean BMI (kg/m229 ± 6.7 31 ± 7.1 29 ± 5.8 25 ± 4.5 
Current smoker (%) 12 
Current drinker (%) 69 51 51 40 
Total energy expenditure from recreational physical activity (METs/week) 12 ± 13.3 11 ± 13.5 11 ± 14.9 14 ± 14.4 
Current postmenopausal hormone use (%) 43 31 42 50 
Nutrient intakes     
    Carbohydrate (% of energy) 52 ± 9.4 52 ± 9.9 53 ± 10.1 56 ± 8.5 
    Protein (% of energy) 17 ± 3.3 16 ± 3.5 16 ± 3.6 16 ± 3.1 
    Fat (% of energy) 31 ± 8.5 33 ± 8.5 31 ± 9.6 29 ± 7.6 
    Dietary fiber (g/day) 17 ± 7.0 14 ± 7.1 16 ± 7.8 15 ± 6.5 
    Total magnesium intake (mg/day)* 335 ± 198 261 ± 170 279 ± 191 277 ± 152 
    Dietary magnesium intake (mg/day) 263 ± 100 222 ± 140 229 ± 127 219 ± 96 
Markers of inflammation     
    hs-CRP (mg/l) 5.01 ± 7.2 5.91 ± 15.4 4.66 ± 5.5 2.11 ± 3.95 
    IL-6 (pg/ml) 3.26 ± 5.0 3.68 ± 4.58 3.14 ± 3.67 2.87 ± 6.24 
    TNF-α-R2 (pg/ml) 2,785 ± 871 2,423 ± 819 2,517 ± 767 2,292 ± 688 
Markers of endothelial dysfunction     
    sICAM-1 (ng/ml) 328 ± 94 270 ± 106 319 ± 103 255 ± 79 
    sVCAM-1 (ng/ml) 819 ± 278 639 ± 224 738 ± 301 690 ± 243 
    E-selectin (ng/ml) 47.0 ± 28.1 45.4 ± 24.5 48.7 ± 28.1 40.2 ± 23.5 
Race/ethnicity
WhiteAfrican AmericanHispanic/LatinoAsian/Pacific Islander
n 1,922 1,123 423 245 
Mean age (years) 64 ± 6.9 61.0 ± 6.7 60 ± 6.8 64 ± 7.6 
Mean BMI (kg/m229 ± 6.7 31 ± 7.1 29 ± 5.8 25 ± 4.5 
Current smoker (%) 12 
Current drinker (%) 69 51 51 40 
Total energy expenditure from recreational physical activity (METs/week) 12 ± 13.3 11 ± 13.5 11 ± 14.9 14 ± 14.4 
Current postmenopausal hormone use (%) 43 31 42 50 
Nutrient intakes     
    Carbohydrate (% of energy) 52 ± 9.4 52 ± 9.9 53 ± 10.1 56 ± 8.5 
    Protein (% of energy) 17 ± 3.3 16 ± 3.5 16 ± 3.6 16 ± 3.1 
    Fat (% of energy) 31 ± 8.5 33 ± 8.5 31 ± 9.6 29 ± 7.6 
    Dietary fiber (g/day) 17 ± 7.0 14 ± 7.1 16 ± 7.8 15 ± 6.5 
    Total magnesium intake (mg/day)* 335 ± 198 261 ± 170 279 ± 191 277 ± 152 
    Dietary magnesium intake (mg/day) 263 ± 100 222 ± 140 229 ± 127 219 ± 96 
Markers of inflammation     
    hs-CRP (mg/l) 5.01 ± 7.2 5.91 ± 15.4 4.66 ± 5.5 2.11 ± 3.95 
    IL-6 (pg/ml) 3.26 ± 5.0 3.68 ± 4.58 3.14 ± 3.67 2.87 ± 6.24 
    TNF-α-R2 (pg/ml) 2,785 ± 871 2,423 ± 819 2,517 ± 767 2,292 ± 688 
Markers of endothelial dysfunction     
    sICAM-1 (ng/ml) 328 ± 94 270 ± 106 319 ± 103 255 ± 79 
    sVCAM-1 (ng/ml) 819 ± 278 639 ± 224 738 ± 301 690 ± 243 
    E-selectin (ng/ml) 47.0 ± 28.1 45.4 ± 24.5 48.7 ± 28.1 40.2 ± 23.5 

Data are means ±SD unless otherwise indicated. n = 3,713.

*Total magnesium intake includes intake from dietary and supplemental sources.

†Dietary magnesium includes intake from diet alone. MET, metabolic equivalent.

Higher dietary magnesium intake was significantly associated with lower concentrations of inflammatory biomarkers including hs-CRP (P for linear trend = 0.003), IL-6 (P for linear trend < 0.0001), and TNF-α-R2 (P for linear trend = 0.0006) (Table 2). Further adjustment for dietary fiber intake attenuated but did not alter the linear trends for hs-CRP (P for linear trend = 0.009), IL-6 (P for linear trend = 0.0005), and TNF-α-R2 (P for linear trend = 0.10) in relation to magnesium intake. After additionally controlling for fruit and vegetable, folate, and saturated and trans fat intake, dietary magnesium intake remained significantly associated with hs-CRP and IL-6. Multivariable adjusted geometric means across increasing quintiles of dietary magnesium were 3.08, 2.63, 2.31, 2.53, and 2.16 mg/l for hs-CRP (P for linear trend = 0.005) and 2.91, 2.63, 2.45, 2.27, and 2.26 pg/ml for IL-6 (P for linear trend = 0.0005).

Table 2

Mean plasma concentrations of biomarkers of inflammation by quintile of dietary magnesium intake among postmenopausal women in the WHI-OS

Dietary magnesium
P for linear trend
Q1Q2Q3Q4Q5
Median (mg/day) 168.5 204.4 233.2 263.1 310.2  
hs-CRP (mg/l)       
    Model 1* 2.89 (2.59–3.23) 2.58 (2.31–2.87) 2.31 (2.07–2.58) 2.60 (2.31–2.92) 2.29 (2.03–2.58) 0.003 
    Model 2 2.99 (2.61–3.41) 2.61 (2.33–2.92) 2.32 (2.07–2.59) 2.57 (2.28–2.90) 2.23 (1.96–2.55) 0.009 
    Model 3 3.08 (2.67–3.55) 2.63 (2.34–2.94) 2.31 (2.07–2.59) 2.53 (2.24–2.86) 2.16 (1.87–2.50) 0.005 
IL-6 (pg/ml)       
    Model 1* 2.91 (2.70–3.13) 2.63 (2.45–2.83) 2.46 (2.28–2.64) 2.28 (2.11–2.46) 2.27 (2.10–2.46) <0.0001 
    Model 2 2.86 (2.62–3.13) 2.62 (2.43–2.82) 2.45 (2.28–2.64) 2.29 (2.11–2.48) 2.30 (2.11–2.51) 0.0005 
    Model 3 2.91 (2.64–3.19) 2.63 (2.44–2.84) 2.45 (2.27–2.64) 2.27 (2.09–2.46) 2.26 (2.05–2.49) 0.0005 
TNF-α-R2 (pg/ml)       
    Model 1* 2,461 (2,392–2,532) 2,506 (2,437–2,577) 2,426 (2,357–2,497) 2,424 (2,352–2,498) 2,338 (2,267–2,411) 0.0006 
    Model 2 2,429 (2,347–2,514) 2,493 (2,422–2,566) 2,423 (2,354–2,494) 2,434 (2,360–2,510) 2,361 (2,282–2,443) 0.10 
    Model 3 2,422 (2,335–2,513) 2,493 (2,421–2,567) 2,422 (2,353–2,493) 2,433 (2,358–2,511) 2,358 (2,270–2,448) 0.15 
sICAM-1 (ng/ml)       
    Model 1* 300 (291–310) 303 (293–313) 300 (290–311) 303 (292–314) 293 (282–304) 0.31 
    Model 2 303 (291–316) 304 (294–315) 300 (290–311) 302 (291–314) 291 (279–303) 0.13 
    Model 3 301 (288–315) 304 (293–315) 300 (290–311) 302 (291–314) 292 (278–305) 0.29 
sVCAM-1 (ng/ml)       
    Model 1* 695 (673–718) 677 (655–699) 673 (651–695) 675 (652–699) 665 (642–689) 0.06 
    Model 2 703 (676–731) 680 (657–703) 673 (651–696) 673 (650–697) 660 (634–686) 0.05 
    Model 3 707 (678–738) 681 (658–704) 673 (651–696) 671 (648–696) 656 (628–685) 0.04 
E-selectin (ng/ml)       
    Model 1* 45.5 (43.2–47.8) 42.5 (40.4–44.7) 40.8 (38.8–43.0) 40.8 (38.7–43.1) 40.7 (38.5–43.0) 0.0007 
    Model 2 43.9 (41.2–46.7) 41.9 (39.8–44.1) 40.7 (38.6–42.9) 41.3 (39.1–43.6) 41.8 (39.4–44.5) 0.43 
    Model 3 43.8 (41.0–46.8) 41.9 (39.7–44.2) 40.7 (38.7–42.9) 41.4 (39.1–43.8) 42.1 (39.4–45.1) 0.62 
Dietary magnesium
P for linear trend
Q1Q2Q3Q4Q5
Median (mg/day) 168.5 204.4 233.2 263.1 310.2  
hs-CRP (mg/l)       
    Model 1* 2.89 (2.59–3.23) 2.58 (2.31–2.87) 2.31 (2.07–2.58) 2.60 (2.31–2.92) 2.29 (2.03–2.58) 0.003 
    Model 2 2.99 (2.61–3.41) 2.61 (2.33–2.92) 2.32 (2.07–2.59) 2.57 (2.28–2.90) 2.23 (1.96–2.55) 0.009 
    Model 3 3.08 (2.67–3.55) 2.63 (2.34–2.94) 2.31 (2.07–2.59) 2.53 (2.24–2.86) 2.16 (1.87–2.50) 0.005 
IL-6 (pg/ml)       
    Model 1* 2.91 (2.70–3.13) 2.63 (2.45–2.83) 2.46 (2.28–2.64) 2.28 (2.11–2.46) 2.27 (2.10–2.46) <0.0001 
    Model 2 2.86 (2.62–3.13) 2.62 (2.43–2.82) 2.45 (2.28–2.64) 2.29 (2.11–2.48) 2.30 (2.11–2.51) 0.0005 
    Model 3 2.91 (2.64–3.19) 2.63 (2.44–2.84) 2.45 (2.27–2.64) 2.27 (2.09–2.46) 2.26 (2.05–2.49) 0.0005 
TNF-α-R2 (pg/ml)       
    Model 1* 2,461 (2,392–2,532) 2,506 (2,437–2,577) 2,426 (2,357–2,497) 2,424 (2,352–2,498) 2,338 (2,267–2,411) 0.0006 
    Model 2 2,429 (2,347–2,514) 2,493 (2,422–2,566) 2,423 (2,354–2,494) 2,434 (2,360–2,510) 2,361 (2,282–2,443) 0.10 
    Model 3 2,422 (2,335–2,513) 2,493 (2,421–2,567) 2,422 (2,353–2,493) 2,433 (2,358–2,511) 2,358 (2,270–2,448) 0.15 
sICAM-1 (ng/ml)       
    Model 1* 300 (291–310) 303 (293–313) 300 (290–311) 303 (292–314) 293 (282–304) 0.31 
    Model 2 303 (291–316) 304 (294–315) 300 (290–311) 302 (291–314) 291 (279–303) 0.13 
    Model 3 301 (288–315) 304 (293–315) 300 (290–311) 302 (291–314) 292 (278–305) 0.29 
sVCAM-1 (ng/ml)       
    Model 1* 695 (673–718) 677 (655–699) 673 (651–695) 675 (652–699) 665 (642–689) 0.06 
    Model 2 703 (676–731) 680 (657–703) 673 (651–696) 673 (650–697) 660 (634–686) 0.05 
    Model 3 707 (678–738) 681 (658–704) 673 (651–696) 671 (648–696) 656 (628–685) 0.04 
E-selectin (ng/ml)       
    Model 1* 45.5 (43.2–47.8) 42.5 (40.4–44.7) 40.8 (38.8–43.0) 40.8 (38.7–43.1) 40.7 (38.5–43.0) 0.0007 
    Model 2 43.9 (41.2–46.7) 41.9 (39.8–44.1) 40.7 (38.6–42.9) 41.3 (39.1–43.6) 41.8 (39.4–44.5) 0.43 
    Model 3 43.8 (41.0–46.8) 41.9 (39.7–44.2) 40.7 (38.7–42.9) 41.4 (39.1–43.8) 42.1 (39.4–45.1) 0.62 

Data are adjusted geometric means (95% CI).

*Model 1 adjusted for matching factors (age, race/ethnicity, clinical center, and time of blood draw), smoking, alcohol, total energy expenditure from recreational physical activity/week, total energy intake, BMI, and case-control status.

†Model 2 adjusted for variables in model 1 plus dietary fiber intake.

‡Model 3 adjusted for variables in model 2 plus fruit and vegetable intake, folate intake, and total saturated and trans fat intake. Q, quintile.

Similarly, we observed significant trends of an inverse association of dietary magnesium intake with concentrations of sVCAM-1 (P for linear trend = 0.06) and E-selectin (P for linear trend = 0.0007) (Table 2). After further adjustment for dietary fiber intake, the inverse association with sVCAM-1 remained strong (P for linear trend = 0.05) and the association with E-selectin was diminished. After additional adjustment for dietary factors, only sVCAM-1 remained significantly associated with dietary magnesium intake; multivariable-adjusted geometric means of sVCAM-1 across increasing quintiles of dietary magnesium were 707, 681, 673, 671, and 656 ng/ml (P for linear trend = 0.04). Tests of variance inflation indicated no serious multicollinearity issues in the models (variance inflation factor <5 for all models).

Assuming a linear relation, an increment of 100 mg/day in dietary magnesium intake was inversely associated with hs-CRP (β = −0.23 ± 0.07; P = 0.002) and IL-6 (β = −0.14 ± 0.05; P = 0.004) (model 3) (Table 3). After correction for measurement error, the association was strengthened for both hs-CRP (β = −0.31 ± 0.10) and IL-6 (β = −0.19 ± 0.07) (data not shown). There was a suggestion that the association of dietary magnesium with hs-CRP concentration varied by ethnicity, with strong associations among white and African American women but no associations among Hispanic and Asian-Pacific Islander women (Pinteraction = 0.05). Inverse associations of dietary magnesium with IL-6 concentration were observed in each ethnicity, without statistical evidence of heterogeneity (Pinteraction = 0.77). Compared with those in normal-weight women (BMI <25 kg/m2), concentrations of hs-CRP and IL-6 were significantly higher among overweight and obese women (BMI ≥25 kg/m2), and inverse correlations with dietary magnesium were more pronounced (Fig. 1,A and B). Similarly, in subgroup analyses stratified by smoking status (Fig. 1 C and D), concentrations of hs-CRP and IL-6 were higher and demonstrated a stronger inverse association among ever smokers than never smokers (P for linear trend among ever smokers: hs-CRP P = 0.01 and IL-6 P = 0.0008). Tests of interaction were also significant for alcohol intake (IL-6 P = 0.04 and E-selectin P = 0.008) and dietary fiber intake (TNF-α-R2 P = 0.05).

Table 3

Linear regression coefficients for the relation between each increase of 100 mg/day in dietary magnesium intake and log-transformed biomarkers of inflammation and endothelial dysfunction among postmenopausal women in the WHI-OS

Ethnicity and biomarkersDietary magnesium
Model 1*Model 2Model 3
All (n = 3,713)    
    hs-CRP (mg/l) −0.12 ± 0.04 (0.004)§ −0.17 ± 0.06 (0.006) −0.23 ± 0.07 (0.002) 
    IL-6 (pg/ml) −0.15 ± 0.03 (<0.0001) −0.12 ± 0.04 (0.005) −0.14 ± 0.05 (0.004) 
    TNF-α-R2 (pg/ml) −0.04 ± 0.01 (0.0004) −0.04 ± 0.02 (0.02) −0.04 ± 0.02 (0.06) 
    sICAM-1 (ng/ml) −0.01 ± 0.01 (0.30) −0.04 ± 0.02 (0.05) −0.03 ± 0.02 (0.15) 
    sVCAM-1 (ng/ml) −0.02 ± 0.01 (0.13) −0.04 ± 0.02 (0.05) −0.04 ± 0.02 (0.07) 
    E-selectin (ng/ml) −0.07 ± 0.02 (0.0005) −0.02 ± 0.03 (0.47) −0.01 ± 0.03 (0.71) 
White (n = 1,922)    
    hs-CRP (mg/l) −0.07 ± 0.05 (0.13) −0.16 ± 0.07 (0.03) −0.27 ± 0.09 (0.004) 
    IL-6 (pg/ml) −0.14 ± 0.04 (0.0001) −0.09 ± 0.05 (0.08) −0.19 ± 0.07 (0.006) 
    TNF-α-R2 (pg/ml) −0.06 ± 0.01 (<0.0001) −0.05 ± 0.02 (0.03) −0.04 ± 0.03 (0.13) 
    sICAM-1 (ng/ml) −0.03 ± 0.01 (0.01) −0.02 ± 0.02 (0.37) −0.02 ± 0.02 (0.41) 
    sVCAM-1 (ng/ml) −0.03 ± 0.02 (0.07) −0.02 ± 0.02 (0.38) −0.03 ± 0.03 (0.30) 
    E-selectin (ng/ml) −0.09 ± 0.03 (0.0003) −0.04 ± 0.04 (0.25) −0.03 ± 0.05 (0.48) 
African American (n = 1,123)    
    hs-CRP (mg/l) −0.17 ± 0.07 (0.02) −0.21 ± 0.11 (0.06) −0.34 ± 0.14 (0.01) 
    IL-6 (pg/ml) −0.18 ± 0.05 (0.0006) −0.11 ± 0.08 (0.16) −0.17 ± 0.10 (0.08) 
    TNF-α-R2 (pg/ml) −0.02 ± 0.02 (0.37) −0.007 ± 0.03 (0.83) −0.008 ± 0.04 (0.83) 
    sICAM-1 (ng/ml) 0.009 ± 0.04 (0.79) −0.08 ± 0.05 (0.12) −0.08 ± 0.07 (0.21) 
    sVCAM-1 (ng/ml) −0.02 ± 0.02 (0.50) −0.04 ± 0.04 (0.24) −0.03 ± 0.04 (0.42) 
    E-selectin (ng/ml) −0.05 ± 0.03 (0.13) −0.01 ± 0.05 (0.80) −0.02 ± 0.06 (0.79) 
Hispanic (n = 423)    
    hs-CRP (mg/l) −0.12 ± 0.10 (0.25) −0.16 ± 0.16 (0.34) 0.07 ± 0.20 (0.73) 
    IL-6 (pg/ml) −0.07 ± 0.08 (0.43) −0.16 ± 0.13 (0.21) −0.03 ± 0.16 (0.87) 
    TNF-α-R2 (pg/ml) −0.04 ± 0.03 (0.19) −0.09 ± 0.05 (0.05) −0.09 ± 0.06 (0.12) 
    sICAM-1 (ng/ml) −0.04 ± 0.03 (0.20) −0.06 ± 0.05 (0.22) 0.01 ± 0.06 (0.85) 
    sVCAM-1 (ng/ml) −0.01 ± 0.04 (0.71) −0.10 ± 0.06 (0.12) −0.14 ± 0.08 (0.07) 
    E-selectin (ng/ml) −0.07 ± 0.06 (0.22) −0.05 ± 0.09 (0.55) −0.07 ± 0.11 (0.51) 
Asian/Pacific Islander (n = 245)    
    hs-CRP (mg/l) −0.14 ± 0.34 (0.68) −0.04 ± 0.52 (0.94) 0.23 ± 0.65 (0.72) 
    IL-6 (pg/ml) −0.36 ± 0.14 (0.01) −0.33 ± 0.21 (0.12) −0.48 ± 0.27 (0.07) 
    TNF-α-R2 (pg/ml) 0.04 ± 0.05 (0.39) 0.001 ± 0.07 (0.98) 0.02 ± 0.09 (0.81) 
    sICAM-1 (ng/ml) 0.08 ± 0.05 (0.11) 0.03 ± 0.08 (0.73) 0.12 ± 0.09 (0.19) 
    sVCAM-1 (ng/ml) 0.02 ± 0.06 (0.71) −0.06 ± 0.09 (0.48) −0.07 ± 0.11 (0.52) 
    E-selectin (ng/ml) 0.09 ± 0.09 (0.30) 0.22 ± 0.13 (0.09) 0.44 ± 0.16 (0.008) 
Ethnicity and biomarkersDietary magnesium
Model 1*Model 2Model 3
All (n = 3,713)    
    hs-CRP (mg/l) −0.12 ± 0.04 (0.004)§ −0.17 ± 0.06 (0.006) −0.23 ± 0.07 (0.002) 
    IL-6 (pg/ml) −0.15 ± 0.03 (<0.0001) −0.12 ± 0.04 (0.005) −0.14 ± 0.05 (0.004) 
    TNF-α-R2 (pg/ml) −0.04 ± 0.01 (0.0004) −0.04 ± 0.02 (0.02) −0.04 ± 0.02 (0.06) 
    sICAM-1 (ng/ml) −0.01 ± 0.01 (0.30) −0.04 ± 0.02 (0.05) −0.03 ± 0.02 (0.15) 
    sVCAM-1 (ng/ml) −0.02 ± 0.01 (0.13) −0.04 ± 0.02 (0.05) −0.04 ± 0.02 (0.07) 
    E-selectin (ng/ml) −0.07 ± 0.02 (0.0005) −0.02 ± 0.03 (0.47) −0.01 ± 0.03 (0.71) 
White (n = 1,922)    
    hs-CRP (mg/l) −0.07 ± 0.05 (0.13) −0.16 ± 0.07 (0.03) −0.27 ± 0.09 (0.004) 
    IL-6 (pg/ml) −0.14 ± 0.04 (0.0001) −0.09 ± 0.05 (0.08) −0.19 ± 0.07 (0.006) 
    TNF-α-R2 (pg/ml) −0.06 ± 0.01 (<0.0001) −0.05 ± 0.02 (0.03) −0.04 ± 0.03 (0.13) 
    sICAM-1 (ng/ml) −0.03 ± 0.01 (0.01) −0.02 ± 0.02 (0.37) −0.02 ± 0.02 (0.41) 
    sVCAM-1 (ng/ml) −0.03 ± 0.02 (0.07) −0.02 ± 0.02 (0.38) −0.03 ± 0.03 (0.30) 
    E-selectin (ng/ml) −0.09 ± 0.03 (0.0003) −0.04 ± 0.04 (0.25) −0.03 ± 0.05 (0.48) 
African American (n = 1,123)    
    hs-CRP (mg/l) −0.17 ± 0.07 (0.02) −0.21 ± 0.11 (0.06) −0.34 ± 0.14 (0.01) 
    IL-6 (pg/ml) −0.18 ± 0.05 (0.0006) −0.11 ± 0.08 (0.16) −0.17 ± 0.10 (0.08) 
    TNF-α-R2 (pg/ml) −0.02 ± 0.02 (0.37) −0.007 ± 0.03 (0.83) −0.008 ± 0.04 (0.83) 
    sICAM-1 (ng/ml) 0.009 ± 0.04 (0.79) −0.08 ± 0.05 (0.12) −0.08 ± 0.07 (0.21) 
    sVCAM-1 (ng/ml) −0.02 ± 0.02 (0.50) −0.04 ± 0.04 (0.24) −0.03 ± 0.04 (0.42) 
    E-selectin (ng/ml) −0.05 ± 0.03 (0.13) −0.01 ± 0.05 (0.80) −0.02 ± 0.06 (0.79) 
Hispanic (n = 423)    
    hs-CRP (mg/l) −0.12 ± 0.10 (0.25) −0.16 ± 0.16 (0.34) 0.07 ± 0.20 (0.73) 
    IL-6 (pg/ml) −0.07 ± 0.08 (0.43) −0.16 ± 0.13 (0.21) −0.03 ± 0.16 (0.87) 
    TNF-α-R2 (pg/ml) −0.04 ± 0.03 (0.19) −0.09 ± 0.05 (0.05) −0.09 ± 0.06 (0.12) 
    sICAM-1 (ng/ml) −0.04 ± 0.03 (0.20) −0.06 ± 0.05 (0.22) 0.01 ± 0.06 (0.85) 
    sVCAM-1 (ng/ml) −0.01 ± 0.04 (0.71) −0.10 ± 0.06 (0.12) −0.14 ± 0.08 (0.07) 
    E-selectin (ng/ml) −0.07 ± 0.06 (0.22) −0.05 ± 0.09 (0.55) −0.07 ± 0.11 (0.51) 
Asian/Pacific Islander (n = 245)    
    hs-CRP (mg/l) −0.14 ± 0.34 (0.68) −0.04 ± 0.52 (0.94) 0.23 ± 0.65 (0.72) 
    IL-6 (pg/ml) −0.36 ± 0.14 (0.01) −0.33 ± 0.21 (0.12) −0.48 ± 0.27 (0.07) 
    TNF-α-R2 (pg/ml) 0.04 ± 0.05 (0.39) 0.001 ± 0.07 (0.98) 0.02 ± 0.09 (0.81) 
    sICAM-1 (ng/ml) 0.08 ± 0.05 (0.11) 0.03 ± 0.08 (0.73) 0.12 ± 0.09 (0.19) 
    sVCAM-1 (ng/ml) 0.02 ± 0.06 (0.71) −0.06 ± 0.09 (0.48) −0.07 ± 0.11 (0.52) 
    E-selectin (ng/ml) 0.09 ± 0.09 (0.30) 0.22 ± 0.13 (0.09) 0.44 ± 0.16 (0.008) 

Data are means ± SEM (P). n = 3,713.

*Model 1 adjusted for matching factors (age, race/ethnicity, clinical center, and time of blood draw), smoking, alcohol, total energy expenditure/week, total energy intake, BMI, and case-control status.

†Model 2 adjusted for variables in model 1 plus dietary fiber.

‡Model 3 adjusted for variables in model 2 plus fruit, vegetable, folate intake, and total saturated and trans fat intake.

§P values are from multiple linear regression models for the relation between dietary magnesium intake (per 100 mg/day increase) and log-transformed biomarkers.

Figure 1

Multivariable adjusted means of hs-CRP (mg/l) and IL-6 (pg/ml) across increasing quintiles of dietary magnesium stratified by BMI (BMI <25 kg/m2 [n = 1,047] and BMI ≥25 kg/m2 [n = 2,666]) (A and B) and smoking status (never smokers [n = 1,959] and ever smokers [including past and current smokers, n = 1,707]) (C and D). Models are adjusted for matching factors (age, race/ethnicity, clinical center, and time of blood draw), smoking, alcohol, total energy expenditure/week, total energy intake, BMI, type 2 diabetes status, dietary fiber intake, fruit and vegetable intake, folate intake, and trans and saturated fat intake (model 3). Tests of linear trend were conducted by using the median value of each quintile as a continuous variable in the model.

Figure 1

Multivariable adjusted means of hs-CRP (mg/l) and IL-6 (pg/ml) across increasing quintiles of dietary magnesium stratified by BMI (BMI <25 kg/m2 [n = 1,047] and BMI ≥25 kg/m2 [n = 2,666]) (A and B) and smoking status (never smokers [n = 1,959] and ever smokers [including past and current smokers, n = 1,707]) (C and D). Models are adjusted for matching factors (age, race/ethnicity, clinical center, and time of blood draw), smoking, alcohol, total energy expenditure/week, total energy intake, BMI, type 2 diabetes status, dietary fiber intake, fruit and vegetable intake, folate intake, and trans and saturated fat intake (model 3). Tests of linear trend were conducted by using the median value of each quintile as a continuous variable in the model.

Close modal

In this large, ethnically diverse cohort of postmenopausal women, dietary magnesium intake was inversely associated with plasma concentrations of hs-CRP, IL-6, TNF-α-R2, sVCAM-1, and E-selectin independent of known risk factors for metabolic outcomes. Adjustment for dietary fiber intake attenuated but did not significantly alter these associations except in the case of E-selectin. After further adjustment for fruit and vegetable intake, folate intake, and saturated and trans fat intake, these inverse trends remained significant for hs-CRP, IL-6, and sVCAM-1, suggesting that dietary magnesium may influence concentrations of these biomarkers independently of other dietary factors associated with inflammation.

Our findings support the notion that magnesium intake improves systemic inflammation and endothelial dysfunction and may play a role in the prevention of type 2 diabetes and metabolic syndrome, a longstanding relation with causality yet to be confirmed. These data are consistent with a considerable body of experimental evidence in animals suggesting that acute magnesium deficiency leads to an inflammatory response (5). Observational data in humans provide additional support for this relation. To date, several cross-sectional studies have reported a link between both low dietary magnesium intake (1,6) and serum magnesium concentrations (19) and elevated hs-CRP in white populations. Fiber intake and dietary patterns high in magnesium were also inversely associated with hs-CRP concentrations in the Nurses' Health Study (8) and in NHANES 1999–2000 (20). However, the relation of magnesium intake to IL-6 and TNF-α is less clear. No association was reported between dietary magnesium intake and TNF-α-R2 or IL-6 in the Nurses' Health Study (6). However, a “western” dietary pattern, lower in magnesium-containing foods, was found to be associated with elevated IL-6 and other markers of inflammation and endothelial dysfunction (8). Our findings provide evidence that hs-CRP and IL-6 may serve as sensitive markers of inflammation that may directly benefit from increased magnesium intake through dietary sources.

CRP is an acute-phase reactant secreted by the liver in response to inflammatory cytokines including IL-6 and TNF-α and is an independent predictor of cardiovascular disease (21) and type 2 diabetes (11). IL-6 and TNF-α are proinflammatory cytokines secreted by macrophages and T-cells to stimulate an immune response to trauma. Low plasma magnesium concentrations and the subsequent disruption in intracellular magnesium homeostasis may play a role in activating the inflammatory response (22). Because hs-CRP is a more sensitive and robust marker of systemic inflammation than other inflammatory markers (23), it may be more readily detected. Our findings also suggest that IL-6 may be sensitive to fluctuations in dietary intake of magnesium. Although TNF-α-R2, a cell surface receptor believed to modulate the action of TNF-α, was inversely associated with dietary magnesium intake before adjustment for dietary fiber intake, this relation was attenuated after adjustment, suggesting that the inverse association with TNF-α-R2 is most likely partially explained by the association with dietary fiber.

With regard to endothelial dysfunction, we observed that dietary magnesium was inversely associated with plasma concentrations of sVCAM-1 independently of other dietary factors. sVCAM-1 and sICAM-1 are cellular adhesion molecules belonging to the immunoglobulin family and are primarily involved in the attachment and transendothelial migration of leukocytes in response to inflammatory cytokines (24). We observed no association between dietary magnesium intake and plasma concentrations of sICAM-1, a finding consistent with a cross-sectional study in the Nurses' Health Study (6). However, we observed a modest association with sVCAM-1 that remained significant even after adjustment for dietary factors associated with endothelial dysfunction and cardiovascular disease. Although the biological explanation for the variability in results across markers is not clear, these findings further support the link between low magnesium intake and elevated concentrations of certain markers of endothelial dysfunction. E-selectin is a cellular adhesion molecule found primarily on the surface of stimulated endothelial cells and mediates the initial rolling of leukocytes along the endothelium (25). In the current study, we observed an inverse association of dietary magnesium intake with E-selectin that disappeared after we accounted for dietary factors.

In this multiethnic cohort of women, we observed notable variation in strengths of association across ethnicity. To our knowledge, no previous work has examined potential ethnic differences in the relation of magnesium intake to systemic inflammation and endothelial dysfunction. Our findings of possible interactions in the current study should be interpreted with caution (i.e., hypothesis-generating) because ethnicity-specific sample sizes were small and the differences could partially be due to residual confounding from demographic and lifestyle factors. More importantly, the generally consistent patterns across the four ethnic groups provide additional evidence to support the notion that increased magnesium intake may have beneficial effects on alleviation of systemic inflammation and endothelial dysfunction. We also observed stronger associations of dietary magnesium intake with hs-CRP and IL-6 concentrations among subgroups with the highest concentrations of these inflammatory markers, i.e., overweight women and smokers. Similar findings among these high-risk subgroups were reported in the Women's Health Study (1), suggesting that higher magnesium intake may be most beneficial among women who are predisposed to systemic inflammation.

There are several limitations that merit consideration. First, the measurement of dietary magnesium intake may be inaccurate because of self-report inconsistencies; however, magnesium intake assessed by our FFQ has a correlation of 0.7 when validated against dietary records (17). Furthermore, in analyses that corrected for measurement error, the relation between magnesium intake and biomarkers was strengthened. Second, dietary magnesium intake is highly correlated with several nutrients including dietary fiber, potassium, and folate, and magnesium is found in high concentrations in foods such as whole grains, nuts, and fruits and vegetables. Therefore, parsing out the independent effects of dietary magnesium is a challenge. In the current study, we sought to examine the independent effects of dietary magnesium through adjustment for dietary fiber as well as fruit and vegetable intake, folate intake, and saturated and trans fat intake in multivariable-adjusted models to control for potential confounding. Our findings suggest that dietary magnesium is associated with several markers of inflammation and endothelial dysfunction independent of these dietary factors, although we could not completely exclude the possibility of residual confounding. This, coupled with the cross-sectional design, does limit our ability to make causal inferences regarding the effect of magnesium intake on markers of inflammation and endothelial dysfunction.

In summary, we found that dietary intake of magnesium was independently and inversely associated with plasma concentrations of hs-CRP, IL-6, and sVCAM-1 in postmenopausal women. These findings are consistent with those of previous studies mostly in whites and support the notion that diets high in magnesium-rich foods including whole grains, nuts, and leafy green vegetables should be encouraged for metabolic disease prevention.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

The WHI program was funded by the National Heart, Lung, and Blood Institute, National Institutes of Health (NIH), and U.S. Department of Health and Human Services through contracts N01-WH-22110, 24152, 32100-2, 32105-6, 32108-9, 32111-13, 32115, 32118-32119, 32122, 42107-26, 42129-32, and 44221. This study was supported by the National Institute of Diabetes and Digestive and Kidney Diseases, NIH (R01-DK-062290) and the Burroughs Wellcome Fund Institutional Program Unifying Population and Laboratory-Based Sciences. Y.S. was supported by a grant (K01-DK-078846) from the National Institute of Diabetes and Digestive and Kidney Diseases, NIH.

No potential conflicts of interest relevant to this article were reported.

We thank the WHI investigators and staff for their dedication and the study participants for making the program possible.

1.
Song
Y
,
Ridker
PM
,
Manson
JE
,
Cook
NR
,
Buring
JE
,
Liu
S
.
Magnesium intake, C-reactive protein, and the prevalence of metabolic syndrome in middle-aged and older U.S. women
.
Diabetes Care
2005
; 
28
:
1438
1444
2.
Song
Y
,
Manson
JE
,
Buring
JE
,
Liu
S
.
Dietary magnesium intake in relation to plasma insulin levels and risk of type 2 diabetes in women
.
Diabetes Care
2004
; 
27
:
59
65
3.
Al-Delaimy
WK
,
Rimm
EB
,
Willett
WC
,
Stampfer
MJ
,
Hu
FB
.
Magnesium intake and risk of coronary heart disease among men
.
J Am Coll Nutr
2004
; 
23
:
63
70
4.
Larsson
SC
,
Bergkvist
L
,
Wolk
A
.
Magnesium intake in relation to risk of colorectal cancer in women
.
JAMA
2005
; 
293
:
86
89
5.
Malpuech-Brugère
C
,
Nowacki
W
,
Daveau
M
,
Gueux
E
,
Linard
C
,
Rock
E
,
Lebreton
J
,
Mazur
A
,
Rayssiguier
Y
.
Inflammatory response following acute magnesium deficiency in the rat
.
Biochim Biophys Acta
2000
; 
1501
:
91
98
6.
Song
Y
,
Li
TY
,
van Dam
RM
,
Manson
JE
,
Hu
FB
.
Magnesium intake and plasma concentrations of markers of systemic inflammation and endothelial dysfunction in women
.
Am J Clin Nutr
2007
; 
85
:
1068
1074
7.
Rodriguez-Morán
M
,
Guerrero-Romero
F
.
Elevated concentrations of TNF-α are related to low serum magnesium levels in obese subjects
.
Magn Res
2004
; 
17
:
189
196
8.
Lopez-Garcia
E
,
Schulze
MB
,
Fung
TT
,
Meigs
JB
,
Rifai
N
,
Manson
JE
,
Hu
FB
.
Major dietary patterns are related to plasma concentrations of markers of inflammation and endothelial dysfunction
.
Am J Clin Nutr
2004
; 
80
:
1029
1035
9.
Design of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group
.
Control Clin Trials
1998
; 
19
:
61
109
10.
Hays
J
,
Hunt
JR
,
Hubbell
FA
,
Anderson
GL
,
Limacher
M
,
Allen
C
,
Rossouw
JE
.
The Women's Health Initiative recruitment methods and results
.
Ann Epidemiol
2003
; 
13
:
S18
S77
11.
Liu
S
,
Tinker
L
,
Song
Y
,
Rifai
N
,
Bonds
DE
,
Cook
NR
,
Heiss
G
,
Howard
BV
,
Hotamisligil
GS
,
Hu
FB
,
Kuller
LH
,
Manson
JE
.
A prospective study of inflammatory cytokines and diabetes mellitus in a multiethnic cohort of postmenopausal women
.
Arch Intern Med
2007
; 
167
:
1676
1685
12.
Song
Y
,
Manson
JE
,
Tinker
L
,
Rifai
N
,
Cook
NR
,
Hu
FB
,
Hotamisligil
GS
,
Ridker
PM
,
Rodriguez
BL
,
Margolis
KL
,
Oberman
A
,
Liu
S
.
Circulating levels of endothelial adhesion molecules and risk of diabetes in an ethnically diverse cohort of women
.
Diabetes
2007
; 
56
:
1898
1904
13.
White
E
,
Shattuck
AL
,
Kristal
AR
,
Urban
N
,
Prentice
RL
,
Henderson
MM
,
Insull
W
 Jr
,
Moskowitz
M
,
Goldman
S
,
Woods
MN
.
Maintenance of a low-fat diet: follow-up of the Women's Health Trial
.
Cancer Epidemiol Biomarkers Prev
1992
; 
1
:
315
323
14.
Kristal
AR
,
Feng
Z
,
Coates
RJ
,
Oberman
A
,
George
V
.
Associations of race/ethnicity, education, and dietary intervention with the validity and reliability of a food frequency questionnaire: the Women's Health Trial Feasibility Study in Minority Populations
.
Am J Epidemiol
1997
; 
146
:
856
869
15.
Schakel
SF
,
Sievert
YA
,
Buzzard
IM
.
Sources of data for developing and maintaining a nutrient database
.
J Am Diet Assoc
1988
; 
88
:
1268
1271
16.
Willett
WC
,
Howe
GR
,
Kushi
LH
.
Adjustment for total energy intake in epidemiologic studies
.
Am J Clin Nutr
1997
; 
65
:
1220S
1231S
17.
Patterson
RE
,
Kristal
AR
,
Tinker
LF
,
Carter
RA
,
Bolton
MP
,
Agurs-Collins
T
.
Measurement characteristics of the Women's Health Initiative food frequency questionnaire
.
Ann Epidemiol
1999
; 
9
:
178
187
18.
Rosner
B
,
Willett
WC
,
Spiegelman
D
.
Correction of logistic regression relative risk estimates and confidence intervals for systematic within-person measurement error
.
Stat Med
1989
; 
8
:
1051
1069
;
discussion 1071–1073
19.
Rodríguez-Morán
M
,
Guerrero-Romero
F
.
Serum magnesium and C-reactive protein levels
.
Arch Dis Child
2008
; 
93
:
676
680
20.
Ajani
UA
,
Ford
ES
,
Mokdad
AH
.
Dietary fiber and C-reactive protein: findings from National Health and Nutrition Examination Survey data
.
J Nutr
2004
; 
134
:
1181
1185
21.
Ridker
PM
,
Hennekens
CH
,
Buring
JE
,
Rifai
N
.
C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women
.
N Engl J Med
2000
; 
342
:
836
843
22.
Paolisso
G
,
Barbagallo
M
.
Hypertension, diabetes mellitus, and insulin resistance: the role of intracellular magnesium
.
Am J Hypertens
1997
; 
10
:
346
355
23.
Rifai
N
,
Ridker
PM
.
High-sensitivity C-reactive protein: a novel and promising marker of coronary heart disease
.
Clin Chem
2001
; 
47
:
403
411
24.
Albelda
SM
,
Smith
CW
,
Ward
PA
.
Adhesion molecules and inflammatory injury
.
FASEB J
1994
; 
8
:
504
512
25.
Schram
MT
,
Stehouwer
CD
.
Endothelial dysfunction, cellular adhesion molecules and the metabolic syndrome
.
Horm Metab Res
2005
; 
37
(
Suppl. 1
):
49
55
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.